Merit Medical Systems (MMSI) Projected to Post Earnings on Thursday

Merit Medical Systems (NASDAQ:MMSI) is anticipated to post its Q3 2025 results after the market closes on Thursday, October 30th. Analysts expect Merit Medical Systems to post earnings of $0.82 per share and revenue of $371.6940 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, October 30, 2025 at 5:00 PM ET.

Merit Medical Systems (NASDAQ:MMSI) last released its quarterly earnings results on Wednesday, July 30th. The medical instruments supplier reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.16. The business had revenue of $382.46 million for the quarter, compared to analyst estimates of $372.47 million. Merit Medical Systems had a net margin of 8.31% and a return on equity of 15.07%. The firm’s revenue was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.92 earnings per share. On average, analysts expect Merit Medical Systems to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Merit Medical Systems Price Performance

Shares of MMSI opened at $82.79 on Wednesday. The company has a market capitalization of $4.90 billion, a price-to-earnings ratio of 42.03, a P/E/G ratio of 2.66 and a beta of 0.58. Merit Medical Systems has a fifty-two week low of $78.12 and a fifty-two week high of $111.45. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.09 and a quick ratio of 2.66. The business’s 50-day moving average is $85.09 and its 200-day moving average is $89.38.

Insider Buying and Selling

In related news, Director Lynne N. Ward sold 3,000 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $88.56, for a total value of $265,680.00. Following the transaction, the director owned 12,809 shares in the company, valued at approximately $1,134,365.04. This represents a 18.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 3.70% of the company’s stock.

Hedge Funds Weigh In On Merit Medical Systems

A number of hedge funds have recently added to or reduced their stakes in MMSI. EverSource Wealth Advisors LLC grew its holdings in Merit Medical Systems by 745.9% during the second quarter. EverSource Wealth Advisors LLC now owns 922 shares of the medical instruments supplier’s stock valued at $86,000 after purchasing an additional 813 shares during the last quarter. State of Wyoming acquired a new position in Merit Medical Systems during the second quarter valued at approximately $162,000. Cerity Partners LLC grew its holdings in Merit Medical Systems by 9.1% during the second quarter. Cerity Partners LLC now owns 3,019 shares of the medical instruments supplier’s stock valued at $282,000 after purchasing an additional 251 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new position in Merit Medical Systems during the second quarter valued at approximately $292,000. Finally, FORA Capital LLC acquired a new position in Merit Medical Systems during the second quarter valued at approximately $325,000. Institutional investors and hedge funds own 99.66% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on MMSI. Needham & Company LLC reiterated a “buy” rating and issued a $108.00 target price on shares of Merit Medical Systems in a report on Friday, July 18th. Zacks Research upgraded Merit Medical Systems from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. Canaccord Genuity Group upped their target price on Merit Medical Systems from $103.00 to $104.00 and gave the company a “buy” rating in a report on Thursday, October 16th. Wells Fargo & Company dropped their target price on Merit Medical Systems from $108.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, July 31st. Finally, Piper Sandler dropped their target price on Merit Medical Systems from $110.00 to $105.00 and set an “overweight” rating on the stock in a report on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $106.50.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.